Research shows that allowing nurse anesthetists to do their jobs without physician supervision does not pose additional risk to patients. Regulations and laws which limit this ability should therefore be eliminated.
Medicaid programs, and other third-party payers, can save a lot of money by requiring use of generics when available. Some state laws, however, can significantly inhibit generic use, according to new research in Health Affairs.
The new health law attempts to dictate how much of insurance premiums insurers must spend on medical care, so of course there is now extensive haggling on defining the calculation. The NAIC has released its version, which now goes to HHS for review.
The Food and Drug Administration has been reviewing its 510(k) process, which is used for many medical device approvals. Two preliminary reports contain a series of recommendations designed to provide greater predictability in the process, while ensuring identification of significant safety concerns.
Personalized medicine relies on genetic testing for much of its information. Direct-to-consumer genetic testing firms are widespread and a GAO report reveals that much of their work appears shoddy and their marketing deceptive. More regulation appears needed and on the way.
Wireless or mobile communication technologies are enjoying a rapid spread in health care. Two of the primary federal agencies which might impact the development and spread of these technologies are the FCC and the FDA, which have agreed to work together in regulating them.
A critical component of personalized medicine is various molecular diagnostic tests. AHRQ has issued a lengthy report on the state of these tests, examining their quality and clinical utility.
An FDA lawyer posts an excellent summary of potential issues in regard to FDA’s regulation of mobile health devices and services. He suggests that industry adopt a proactive approach of proposing sensible regulations and guidance to FDA.